InvestorsHub Logo

DarthYoda

02/17/20 9:00 AM

#24136 RE: sleekscape #24123

Sleek, for the sake of brevity, I have to simply ask, in a CBD isolate-only industry, what would separate CBD food, dietary supplements, and drugs, besides the dosage amount?

1 CBD cookie= Food?
2 CBD cookies= Dietary Supplement?
3 CBD cookies= an FDA Approved Drug?

I don't think this is any way to really regulate anything as I can just eat 3x food to have a drug.

Also, I don't look at the House Bill as something that the FDA has a say in, not only because the FDA does not make legislation, but because the bill would not be necessary at all if congress agreed with the approach the FDA has taken to regulate hemp this past year, which so far has been to just hide behind their conspicuously timed approval of Epidiolex.

No, I see the house bill as a message to the FDA, that if they don't get their butts in gear to regulate, Congress will override them and do their job for them, in a way they wont like.

So, what is it, in your opinion, aside from dosage amount, that would separate the three categories for CBD products, in an isolate only industry?

DarthYoda

02/17/20 1:40 PM

#24144 RE: sleekscape #24123

Sorry, one more batch of DD here, but I don't believe Congress intends on going back and forth with the FDA over 100+ of each and every cannabinoid throughout the next millennium. FDA has ZERO IND preclusion in order to do so for secondary cannabinoids anyway. They can't just make one up.

Congress obligated FDA and USDA with regulating hemp when they passed the Farm Bill. However, the FDA said it would take them "at least several years" to be able to do so. Congress told the FDA that timeframe is "unacceptable" and has given the FDA 180 days from December 20th, 2019 to provide a CBD market study to congress that gives the current state of "mislabeling" and "adulteration" in the industry. IMO, it will be very interesting to hear the parameters that the FDA uses to define the two concepts within the CBD/hemp industry, especially "adulteration", as I believe the FDA's presentation on that topic may offer clues, or even industry-wide guidance, for acceptable product development.

Congress is definitely more interested in a cannabinoid industry, and not just a cannabidiol industry.

CBG is the "stem cell" cannabinoid, in that it can turn into most other cannabinoids. So, understanding more about CBG specifically will contribute very much to understanding the whole plant, as well as the entourage effect:

"Senate Committee Calls For Enhanced CBD And CBG Cannabis Compound Research"
September 19, 2019

“Cannabis Research—The Committee believes that cannabidiol [CBD] and cannabigerol [CBG], compounds found in cannabis, may provide beneficial medicinal effects. However, there is insufficient scientific information about the long-term effects of these compounds. Additional, coordinated research on a national scale could help determine the toxicology and medicinal effects of CBD and CBG. The Committee encourages NIH to consider additional investment in studying the medicinal effects and toxicology of CBD and CBG.”


https://timesofcbd.com/senate-committee-calls-for-enhanced-cbd-and-cbg-cannabis-compound-research/

Congress is also directing FDA to “perform a sampling study of the current CBD marketplace to determine the extent to which products are mislabeled or adulterated” and report back to lawmakers within 180 days.
Separately, lawmakers set aside nearly $16.5 million in funding to support the implementation of a domestic hemp program under the 2018 Farm Bill, which legalized the crop and its derivatives.


https://www.marijuanamoment.net/congress-attaches-marijuana-hemp-and-cbd-provisions-to-federal-spending-bills/

HeatfoX

02/17/20 9:10 PM

#24146 RE: sleekscape #24123

Run for the hills -90% quickly turns to -99% and -99,9%

1,500,000,000 AS
Cayman island
1:(insane amount) RS
Going to 0,0001